FindTrial
Sign In

Studying the effects of parenteral glutamine supplementation in children with sepsis

Studying the effects of parenteral glutamine supplementation as immunonutrition in children with sepsis- A randomized control trial - nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/10/096087
Enrollment
50
Registered
2025-10-15
Start date
Unknown
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: A00-B99- Certain infectious and parasitic diseases Health Condition 2: D50-D89- Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism Health Condition 3: I00-I99- Diseases of the circulatory system Health Condition 4: K00-K95- Diseases of the digestive system Health Condition 5: J00-J99- Diseases of the respiratory system Health Condition 6: V00-Y99- External causes of morbidity

Interventions

Intervention1: L-alanyl-l-glutamine dipeptide infusion (20gm/100ml): L-alanyl-l-glutamine dipeptide infusion(20gm/100ml) at a dose of 0.3g/kg/day by intravenous infusion through iv cannula once daily

Sponsors

Sheetal Jena
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients aged 1 month to 18 years with a clinical diagnosis of sepsis defined by the Society of Critical Care Medicine, Pediatric Sepsis Definition Task Force (2024) as a Phoenix Sepsis Score of more than or equal 2 , based on organ dysfunction in any of the four systems, respiratory, cardiovascular, coagulation, or neurological and in the presence of suspected or confirmed infection

Exclusion criteria

Exclusion criteria: Patients suffering from Inborn error of metabolism - maple syrup urine disease, phenylketonuria, tyrosinemia, homocystinuria. Patients receiving high dose of immunosuppressant or steroids Patients with chronic kidney disease or end stage liver disease

Design outcomes

Primary

MeasureTime frame
To assess the effect of parenteral glutamine supplementation on morbidity and mortality of children with sepsis using PELOD (Paediatric Logistics Organ Dysfunction) 2 scoreTimepoint: 1 year hospital based study—

Secondary

MeasureTime frame
To observe its effects on biochemical parameters -total leucocyte counts, serum albumin and serum high sensitivity C reactive protein levelsTimepoint: 1 year hospital based study—

Countries

India

Contacts

Public ContactSheetal Jena

KLE academy of Higher Education and Research

tanmayametgud@rediffmail.com9845395294

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026